甲状腺眼病的管理:美国甲状腺协会与欧洲甲状腺协会共识声明
甲状腺眼病(TED)的评估与管理仍具挑战,新疗法的具体作用尚待明确。多数TED患者在接受甲亢治疗期间出现眼部表现并由内分泌科医生照护,因此内分泌科医生在诊断、初始管理及筛选需转诊专科治疗的患者中起关键作用。鉴于指导需求超越国界,美国甲状腺协会与欧洲甲状腺协会联合制定本共识声明。
要点
- 多数TED患者在接受甲亢治疗期间出现眼部表现,由内分泌科医生照护。
- 内分泌科医生在TED诊断、初始管理及筛选需转诊专科治疗的患者中起关键作用。
- 新疗法的具体作用仍在确定中。
核心结论
- 美国甲状腺协会与欧洲甲状腺协会联合发布本共识声明,以指导内分泌科医生满足TED患者的需求并促进国际知识交流。
研究设计与样本
- 由美国甲状腺协会与欧洲甲状腺协会联合制定的共识声明。
主要发现
- TED的评估与管理对临床医生仍具挑战。
- 新疗法近期出现,其具体作用仍在确定中。
- 多数TED患者在接受甲亢治疗期间出现眼部表现并由内分泌科医生照护。
临床怎么用
- 内分泌科医生在TED诊断、初始管理及选择需转诊专科治疗的患者中起关键作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this consensus statement.
引用
- Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022. PMID: 36480280. doi:10.1089/thy.2022.0251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。